Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.495 AUD | -3.88% | -16.10% | -13.16% |
28/05 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
28/05 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.16% | 22Cr | |
+48.64% | 5.46TCr | |
-6.44% | 3.99TCr | |
+37.07% | 3.88TCr | |
+14.28% | 2.69TCr | |
-11.17% | 2.62TCr | |
-21.40% | 1.88TCr | |
+25.64% | 1.22TCr | |
+0.96% | 1.22TCr | |
+27.04% | 1.19TCr |
- Stock Market
- Equities
- OPT Stock
- News Opthea Limited
- Opthea Names Joel Naor as Chief Medical Officer